tirzepatide not compounded vs regular tirzepatide: key differences Tirzepatide-Weightloss - Sprout Health

Wegovy targets just the GLP-1 receptor, while Tirzepatide targets both GLP-1 and GIP receptors

Journal of Clinical Oncology, 24(18), 2932-2947

Documented BMI of 30 kg/m or greater, or BMI of 27 kg/m or greater with at least one qualifying comorbidity

If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated Tell your healthcare provider right away if you get symptoms of gallbladder problems which may include: pain in your upper stomach (abdomen) fever yellowing of skin or eyes (jaundice) clay-colored stools Low Blood Sugar (Hypoglycemia) Your risk for getting low blood sugar may be higher if you use MOUNJARO with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin Signs and symptoms of low blood sugar may include: dizziness or light-headedness sweating confusion or drowsiness headache blurred vision slurred speech shakiness fast heartbeat anxiety, irritability, or mood changes hunger weakness feeling jittery Concomitant use with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia The risk of hypoglycemia may be lowered by reducing the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin

The exact mechanism for weight loss is not fully understood, but reduced energy intake is the primary driver